When a tiny medtech company takes on an industry giant in federal court, you know something interesting is brewing. TELA Bio, Inc. (TELA) has filed an antitrust lawsuit against Becton, Dickinson & Company (BDX), alleging the medical device behemoth wielded its market power like a sledgehammer to keep competition out of the hernia mesh business.

According to the complaint, which Thomson Reuters published online Monday, Becton Dickinson didn't just dominate the hernia mesh market—it allegedly rigged the game to make sure no upstart competitor could gain a foothold, even when doctors preferred the alternative and patients might have benefited.

Two Markets, One Dominant Player

The hernia mesh market breaks down into two main segments. There's permanent mesh, the workhorse low-cost plastic product used in most hernia repairs. Then there's resorbable mesh, a more sophisticated option that integrates into body tissue over time and is typically reserved for complex procedures.

Becton Dickinson controls both worlds, according to the lawsuit. The company allegedly holds roughly 65% of the U.S. permanent hernia mesh market by dollar share and a staggering 77% of the resorbable mesh segment. That kind of market concentration gives you serious leverage over hospital purchasing decisions and pricing power.

After cementing its position in permanent mesh, Becton Dickinson launched its Phasix resorbable mesh line in 2012. By 2016, the lawsuit alleges, the company controlled nearly three-quarters of both markets combined—a level of dominance that would make any antitrust lawyer's ears perk up.

Enter the Underdog

That's when TELA Bio showed up with OviTex, a resorbable mesh made from sheep-derived extracellular matrix reinforced with synthetic fibers. The pitch was compelling: similar or better clinical performance at a price 15% to 45% lower than Phasix.

According to the complaint, physicians increasingly preferred OviTex for its combination of strength, absorption profile, and cost efficiency. In a rational market, that should have been TELA's ticket to meaningful market share. But the hernia mesh market apparently doesn't operate on those principles.

Instead of competing on price or product quality, the lawsuit claims Becton Dickinson leaned on its market power to protect Phasix from this new competitor.

The Contracting Web

Here's where things get interesting from an antitrust perspective. TELA alleges that Becton Dickinson constructed a web of overlapping, multi-year contracts with group purchasing organizations, integrated delivery networks, and individual hospitals. These agreements allegedly tied discounts on Becton Dickinson's high-volume permanent mesh products to restrictions on competing resorbable mesh offerings.

It's a classic bundling strategy: hospitals get better pricing on the commodity product they buy in bulk, but only if they limit their purchases of competing premium products. The result, according to TELA, was that OviTex remained stuck at marginal market share despite physician demand, while Becton Dickinson's higher-priced Phasix stayed entrenched.

Real World Consequences

The lawsuit doesn't just argue abstract market harm. It points to specific patient impacts. In one case detailed in the complaint, a surgeon was denied approval to use OviTex because of the hospital's contracts with Becton Dickinson. The patient's family ended up paying out of pocket for the preferred product, but the patient's condition deteriorated and the patient later died during surgery.

Whether that outcome would have been different with earlier access to OviTex is impossible to say, but it illustrates the real-world stakes when hospital purchasing decisions are driven by contract terms rather than clinical judgment.

A Troubled Track Record

This isn't Becton Dickinson's first rodeo with hernia mesh litigation. In 2022, the company's C.R. Bard unit was ordered to pay $4.8 million over claims related to its hernia repair mesh. The company continues to face more than 30,000 related lawsuits involving its mesh products.

More recently, a Hawaii man filed a new lawsuit alleging severe complications following implantation of Bard's hernia repair mesh. The mounting legal pressure suggests the company's mesh business has become a persistent liability.

What TELA Wants

TELA Bio is seeking damages, injunctive relief, and other remedies to restore competition and expand patient and provider choice in the hernia mesh market. Translation: they want money for past harm, court orders to stop the alleged anticompetitive practices, and a chance to compete on a level playing field going forward.

Whether they'll succeed is anyone's guess. Antitrust cases are notoriously difficult to win, especially against well-resourced defendants. But TELA's specific allegations about bundled contracts and market foreclosure hit some of the classic antitrust pressure points.

Price Action: TELA Bio shares were up 1.75% at $1.15 during premarket trading Tuesday. BDX stock closed at $196.74 Monday.